Connect with us

Spread & Containment

Synthetic droplets cause a stir in the primordial soup

Our bodies are made up of trillions of different cells, each fulfilling their own unique function to keep us alive. Credit: OIST Our bodies are made up…

Published

on

Our bodies are made up of trillions of different cells, each fulfilling their own unique function to keep us alive.

Credit: OIST

Our bodies are made up of trillions of different cells, each fulfilling their own unique function to keep us alive.

How do cells move around inside these extremely complicated systems? How do they know where to go? And how did they get so complicated to begin with? Simple yet profound questions like these are at the heart of curiosity-driven basic research, which focuses on the fundamental principles of natural phenomena. An important example is the process by which cells or organisms move in response to chemical signals in their environment, also known as chemotaxis.

A constellation of researchers from three different research units at the Okinawa Institute of Science and Technology (OIST) came together to answer basic questions about chemotaxis by creating synthetic droplets to mimic the phenomena in the lab, allowing them to precisely isolate, control and study the phenomena. Their results, which helps answering questions about the principles of movement in simple biological systems, have now been published in the Journal of The American Chemical Society. “We have shown that it is possible to make protein droplets migrate through simple chemical interactions,” says Alessandro Bevilacqua, PhD student in the Protein Engineering and Evolution Unit and co-first author on the paper. Professor Paola Laurino, head of the unit and leading author, adds that they “have created a simple system that mimic a very complex phenomenon, and which can be modulated through enzymatic activity.” 

Tensions on the surface

While the process of creating droplets might not sound like the most complicated task, mimicking biological processes as close to reality as possible while keeping accurate control over all the variables certainly is. The synthetic, membrane-less droplets contain a very high concentration of the bovine protein BSA to mimic the crowded conditions inside cells, as well as urease, an enzyme that catalyzes the breakdown of urea into ammonia.

Ammonia is basic, meaning it has a high pH-value. As the enzyme gradually catalyzes the production of ammonia, it diffuses into the solution, creating a ‘halo’ of higher pH around the droplet, which in turn enables droplets to detect other droplets and migrate towards each other.

The researchers found that the key to understanding the chemotaxis of the droplets is the pH-gradient, as it facilitates the Marangoni effect, which describes how molecules flow from areas of high surface tension to low. Surface tension is the measure of energy required to keep molecules at the surface together, like glue. When pH increases, this glue weakens, causing molecules to spread out and lowering surface tension, which in turn makes it easier for molecules to move. You can see this by adding soap, which has a high pH, to one end of a bathtub of still water: the water will flow towards the end with soap because of the Marangoni effect. 

When two synthetic droplets are close enough, their halos interact, raising the pH in the environment between them, which makes them move together. Because the surface tension is still strong on the opposite ends of the droplets, they keep their shape until the surfaces touch, and the cohesive forces within the droplets overcome the surface tension, causing them to merge. As larger droplets both produce more ammonia and have a larger surface area (which decreases surface tension), they attract droplets smaller than themselves.

Collaborating on ancient soup and future biotech

Thanks to the development of these droplets, the researchers have made headway in answering basic questions about biological movement – and in doing so, they have gained insight into the directed movement of the earliest forms of life in the primordial soup billions of years ago, as well as a lead on creating new biologically inspired materials. 

Our knowledge of life as it looked billions of years ago is fuzzy at best. A prominent hypothesis is that life originated in the oceans, as organic molecules gradually assembled and became more sophisticated in a ‘primordial soup’ – and this could have been facilitated by chemotaxis through the Marangoni effect. “It would have been beneficial for droplets to have this mechanism of migration in the hypothetical origin of life scenario,” as Professor Laurino puts it.  This migration could have triggered the formation of primitive metabolic pathways whereby enzymes catalyze a variety of substances that ultimately produce a chemical gradient that drives the droplets together, leading to larger and more sophisticated communities.

The research also points ahead in time, providing leads on new technology. “One example is the creation of responsive materials inspired by biology,” suggests Alessandro Bevilacqua. “We have shown how simple droplets can migrate thanks to a chemical gradient. A future application of this could be technologies that sense or react to chemical gradients, for example in micro-robotics or drug delivery.” 

The work to produce and analyze the synthetic droplets is the result of a combination of deeply integrated interdisciplinarity and the human factors undergirding scientific work. The project began during the coronavirus pandemic, when a member of the Protein Engineering and Evolution Unit was in quarantine with a member of the Complex Fluids and Flows Unit. The two began talking, and though the two units are from two disparate fields – biochemistry and mechanics, respectively – the project evolved in tandem. Eventually, members from the Micro/Bio/Nanofluidics Unit joined the project with sophisticated measurements of the droplets’ surface tension.

The unique non-disciplinary research environment at OIST catalyzed the collaboration. As Professor Laurino puts it, “this project could never have existed if we were separated by departments. It hasn’t been an easy collaboration, because we communicate our field in very different ways – but being physically close made it significantly easier.” Alessandro Bevilacqua joins in: “The coffee factor has been very important. Being able to sit down with other unit members made the process much faster and more productive.” Their cooperation doesn’t stop here – rather, this paper is the beginning of a fruitful partnership between the three units. “We see a lot of synergy in our work, and we work effectively and efficiently together. I don’t see a reason why we should stop,” as Professor Laurino states it. It’s thanks to the combined efforts of the three units that we now know more about the minute movements of life at the smallest, earliest, and possibly future scale.

 

 


Read More

Continue Reading

Government

COVID-19 Vaccine Protection Among Children Plummets Within Months: CDC Study

COVID-19 Vaccine Protection Among Children Plummets Within Months: CDC Study

Authored by Zachary Stieber via The Epoch Times,

Children who…

Published

on

COVID-19 Vaccine Protection Among Children Plummets Within Months: CDC Study

Authored by Zachary Stieber via The Epoch Times,

Children who received an original COVID-19 vaccine have little protection against hospitalization just months after vaccination, according to a new study from the U.S. Centers for Disease Control and Prevention (CDC).

Children initially have 52 percent protection against hospitalization but that estimated effectiveness plummeted to 19 percent after four months, according to the paper.

Protection against so-called critical illness also dropped sharply, from 57 percent to 25 percent, researchers found.

The researchers include CDC employees and the paper was published in the CDC’s weekly digest on April 18.

The study covered children who received two or more doses of the original Pfizer-BioNTech or Moderna COVID-19 vaccines from Dec. 19, 2021, through Oct. 29, 2023.

The study involved children aged 5 to 18 who were hospitalized with acute COVID-19 and tested positive for the illness and compared them to a control group of children hospitalized with COVID-19-like symptoms but who tested negative for COVID-19.

Researchers drew data from the Overcoming COVID-19 Network, which includes health care sites in most of the United States, and ended up with 1,551 case patients and 1,797 in the control group.

The study found that “receipt of ≥2 original monovalent COVID-19 vaccine doses was associated with fewer COVID-19–related hospitalizations in children and adolescents aged 5–18 years; however, protection from original vaccines was not sustained over time,” Laura Zambrano, a CDC epidemiologist, and her co-authors wrote.

It also recorded a similar drop in protection against critical illness, defined as being placed on mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, or dying.

The researchers asserted that the results highlighted the current CDC guidance that all people aged 6 months and older receive one of the newest COVID-19 vaccines, which were introduced in the fall of 2023 with clinical data from just 50 humans and no efficacy estimates. The CDC only publishes papers in its weekly digest, the Morbidity and Mortality Weekly Report, after they’re shaped to “comport with CDC policy.” The papers are not peer-reviewed.

Ms. Zambrano did not respond when asked for data suggesting that the currently available shots provide longer-lasting protection than the original vaccines.

The CDC’s website says, in promoting vaccination, that COVID-19 vaccines are “effective at protecting people from getting seriously ill, being hospitalized, and dying” but the hyperlink that ostensibly supports the statement goes to a page that is not live.

U.S. authorities have been moving COVID-19 vaccines to a once-a-year model, similar to influenza vaccines. The model features updating the formulation of the vaccines on an annual basis, in an acknowledgment that any protection the vaccines give quickly wanes. The formulation is typically updated in the fall.

Just 14 percent of children, and 23 percent of adults, have received one of the newest vaccines as of April 6, according to CDC estimates. The available vaccines are messenger RNA (mRNA) shots from Pfizer and Moderna and an alternative from Novavax.

Dr. Jane Orient, executive director of the Association of American Physicians and Surgeons, noted that, according to the new paper, the maximum effectiveness estimates against hospitalization were 61 percent, regardless of how the data were sliced, that more deaths were recorded among the case patients, and the median hospitalization duration was four days for both groups.

“I do not see how a clinician whose concern is treating patients and whose job does not depend on pushing mRNA vaccines would find this a basis for recommending shots—quite the contrary,” Dr. Orient, who was not involved in the research, told The Epoch Times in an email.

“It reeks of conflict of interest.”

Stated limitations of the paper include not assessing post-infection immunity and a lack of sequencing data.

The conflict of interest section runs 688 words and includes some of the authors reporting funding from Pfizer and Moderna or ownership of Pfizer stock.

Tyler Durden Wed, 04/24/2024 - 21:30

Read More

Continue Reading

International

Identifying proteins causally related to COVID-19, healthspan and lifespan

“[…] we identified multiple proteins affecting COVID-19 and aging.” Credit: 2024 Zhao et al. “[…] we identified multiple proteins affecting COVID-19…

Published

on

“[…] we identified multiple proteins affecting COVID-19 and aging.”

Credit: 2024 Zhao et al.

“[…] we identified multiple proteins affecting COVID-19 and aging.”

BUFFALO, NY- April 24, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 7, entitled, “Using genetics and proteomics data to identify proteins causally related to COVID-19, healthspan and lifespan: a Mendelian randomization study.”

The COVID-19 pandemic poses a heavy burden on public health and accounts for substantial mortality and morbidity. Proteins are building blocks of life, but specific proteins causally related to COVID-19, healthspan and lifespan, have not been systematically examined. In this new study, researchers Jie V. Zhao, Minhao Yao, and Zhonghua Liu from The University of Hong Kong and Columbia University conducted a Mendelian randomization study to assess the effects of 1,361 plasma proteins on COVID-19, healthspan and lifespan, using large GWAS of severe COVID-19 (up to 13,769 cases and 1,072,442 controls), COVID-19 hospitalization (32,519 cases and 2,062,805 controls) and SARS-COV2 infection (122,616 cases and 2,475,240 controls), healthspan (n = 300,477) and parental lifespan (~0.8 million of European ancestry).

“We included both COVID-19 and healthspan and lifespan in the outcome, because COVID-19 which occurred in recent years reflects a new threat to longevity, whilst healthspan and lifespan reflect overall morbidity and mortality.”

The researchers identified 35, 43, and 63 proteins for severe COVID, COVID-19 hospitalization, and SARS-COV2 infection, and 4, 32, and 19 proteins for healthspan, father’s attained age, and mother’s attained age. In addition to some proteins reported previously, such as SFTPD related to severe COVID-19, the team identified novel proteins involved in inflammation and immunity (such as ICAM-2 and ICAM-5 which affect COVID-19 risk, CXCL9, HLA-DRA and LILRB4 for healthspan and lifespan), apoptosis (such as FGFR2 and ERBB4 which affect COVID-19 risk and FOXO3 which affect lifespan) and metabolism (such as PCSK9 which lowers lifespan). They found 2, 2, and 3 proteins shared between COVID-19 and healthspan/lifespan, such as CXADR and LEFTY2, shared between severe COVID-19 and healthspan/lifespan. Three proteins affecting COVID-19 and seven proteins affecting healthspan/lifespan are targeted by existing drugs.

“Our study provided novel insights into protein targets affecting COVID-19, healthspan and lifespan, with implications for developing new treatment and drug repurposing.”

 

Read the full paper: DOI: https://doi.org/10.18632/aging.205711 

Corresponding Authors: Jie V. Zhao, Zhonghua Liu

Corresponding Emails: janezhao@hku.hk, zl2509@cumc.columbia.edu 

Keywords: proteomics, healthspan, lifespan, COVID-19

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

International

CureVac to cut costs, starts GSK-partnered bird flu vaccine trial

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.
It said Wednesday that 150 employees have…

Published

on

CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company.

It said Wednesday that 150 employees have agreed to voluntarily leave the company. The news was first reported last month by German news outlet SWR. CureVac currently has more than 1,100 employees, according to the annual report.

CureVac said its reorganization will lead to savings starting in the second half of the year, and its cash runway is now set to extend into the fourth quarter of 2025. Its stock $CVAC was down about 8% on Wednesday morning.

In its fourth-quarter earnings update, the company also announced that its and GSK’s joint pandemic preparedness agreement with the German government would be terminated at the end of May. Germany had contracted the companies to supply mRNA-based vaccines in the event of a public health emergency. CureVac noted that plans to complete its vaccine manufacturing facility remain unaffected, and the site is expected to be certified in the second half of the year.

Thaminda Ramanayake

On June 1, CureVac will also be getting a new chief business officer. Thaminda Ramanayake was previously CBO at Affini-T Therapeutics.

CureVac also announced the start of a Phase 1/2 study of an H5N1 avian flu vaccine candidate as part of its collaboration with GSK to develop mRNA vaccines. There are escalating concerns about a bird flu pandemic in humans since the disease spread to dairy cows in the US. The FDA on Tuesday reported evidence of the virus in commercial pasteurized milk, but maintained that the pasteurization process is likely to inactivate the virus. The regulator said the commercial milk supply is still safe.

The avian flu vaccine study will test up to five dose levels compared to a placebo control in two groups of adults: those aged 18 to 64 years old, and adults aged 65 to 85.

CureVac’s partnership with GSK began in July 2020, and they were major players in the Covid-19 vaccine race until their vaccine failed a pivotal study and efforts flamed out. They are currently developing a seasonal mRNA flu vaccine, though the partners recently reported mixed data from a Phase 2 trial.

Read More

Continue Reading

Trending